AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that the Company has completed the acquisition of leading oncology research and development company Sapphire Biotech, Inc. (“Sapphire”). In January of this year, AXIM announced that the Company signed a binding term sheet to acquire Sapphire. As part of the acquisition, AXIM has acquired 100 percent of the capital stock of Sapphire and will operate Sapphire as a wholly-owned subsidiary. Sapphire will continue to be led by Catalina Valencia, as Chief Executive Officer.
Read the full article: AXIM® Biotechnologies Completes Acquisition of Oncology Research and Development Company Sapphire Biotech, Inc. //
Source: https://www.globenewswire.com/news-release/2020/03/18/2002620/0/en/AXIM-Biotechnologies-Completes-Acquisition-of-Oncology-Research-and-Development-Company-Sapphire-Biotech-Inc.html